Latent Tuberculosis

Key Mechanism 1: Granuloma Formation and Mycobacterial Sequestration

Key Mechanism 2: Interferon-Gamma–Mediated Immune Response and T-Cell Memory

Key Mechanism 3: Mycobacterial Dormancy and the DosR Regulon

Key Mechanism 4: Lipid Metabolism and Cell Wall Remodeling

Key Mechanism 5: Immune Evasion and Antigenic Tolerance

Acquisition of LTBI: Exposure-Related Factors

• Tuberculosis contact and transmission: LTBI develops following exposure to individuals with active pulmonary or laryngeal TB disease. The risk of transmission per contact exposure is approximately 10–20% depending on infectiousness of the source patient (sputum smear microscopy positivity is a major determinant), duration of exposure, and ventilation conditions. Household contacts, healthcare workers, and incarcerated persons have substantially elevated exposure risk. Close contacts of microbiologically confirmed TB cases have a 20–30% probability of developing LTBI within the first 8 weeks post-exposure.
• Geographic and epidemiological exposure: Individuals living in or traveling to high-TB-burden regions (sub-Saharan Africa, South and Southeast Asia, Eastern Europe) have higher LTBI incidence. Occupational exposures (healthcare workers, laboratory personnel) confer elevated risk.

Progression from LTBI to Active TB Disease: Host Factors

• HIV/AIDS with CD4+ cell depletion: This is the single most significant risk factor for progression from LTBI to active TB disease. Individuals with HIV and CD4+ <50 cells/μL have a 20–37% annual risk of TB reactivation compared to <1% annually in HIV-negative persons. The mechanism is multifactorial: direct loss of CD4+ T cells impairs Th1 responses; HIV infection reduces IFN-γ production; macrophage function is compromised; and protective granulomas may not form adequately. TB in HIV-coinfected individuals is often extrapulmonary and disseminated, with high mortality if not treated.

• Immunosuppressive medications and conditions: Tumor necrosis factor-alpha (TNF-α) is essential for granuloma maintenance, and TNF-α inhibitors (infliximab, etanercept, adalimumab, golimumab, certolizumab pegol) increase TB reactivation risk 4–25 fold (varying by agent and population). The risk is highest in the first 6 months after starting TNF inhibitors. Other immunosuppressive agents including corticosteroids (particularly at doses >15 mg prednisone equivalent daily for ≥1 month), biologics targeting IL-6 or IL-17 pathways, and calcineurin inhibitors increase risk. Patients receiving these therapies should be screened for LTBI and offered preventive therapy.

• Diabetes mellitus: Uncontrolled diabetes approximately doubles the risk of TB progression (and of severe disease if TB develops). Proposed mechanisms include impaired Th1 and Th17 responses, altered macrophage function, reduced IFN-γ production, and impaired granuloma formation. The risk is substantially higher in patients with poor glycemic control and long disease duration.

• Chronic kidney disease and renal failure: End-stage renal disease on hemodialysis increases TB risk 10–25 fold. Uremia impairs lymphocyte function, cell-mediated immunity is compromised, and there may be reduced renal clearance of active TB metabolites. Patients pre- or post-renal transplantation require LTBI screening.

• Malignancy and cancer treatment: Active malignancy and chemotherapy impair immune function. Hematologic malignancies and advanced cancers with constitutional symptoms carry highest risk. Post-transplantation solid organ recipients have 30–200 fold increased TB risk depending on organ and immunosuppression intensity.

• Young age at time of infection: Children with LTBI, especially those <4 years old, have substantially higher progression risk (10–20% over the first 1–5 years) compared to adults. This is particularly critical in high-burden settings where pediatric TB disease and disseminated/miliary TB are more common. The immature adaptive immune response in young children explains this heightened risk.

• Recent TB infection: Individuals with recently acquired LTBI (within the past 2 years) have higher short-term progression risk (~5% in first year) compared to remote infections. This is why contact tracing and treatment of contacts is so critical.

• Severe malnutrition and low body weight: Malnutrition impairs T-cell function, reduces IL-2 and IFN-γ production, and increases susceptibility to both TB infection and progression. A BMI <18.5 kg/m² is associated with increased risk.

• Substance use disorders: Alcohol use disorder, tobacco smoking, and illicit drug use (particularly injected drugs) increase TB progression risk through multiple mechanisms: immunosuppression, nutritional deficiencies, behavioral factors leading to poor adherence, and social vulnerabilities.

• Silicosis and occupational lung disease: Silicosis increases TB risk 3–4 fold; mechanisms include impaired macrophage function and granuloma formation. This is clinically relevant in occupational health screening.

• Gastrectomy and other gastric procedures: Reduced gastric acid impairs nutrient absorption, and these patients have increased TB risk.

• Genetic susceptibility factors: Polymorphisms in genes regulating innate immunity (TIRAP, IL-1 receptor-associated kinase, TLR genes) and adaptive immunity (IL-10, TNF-α genes) influence TB progression risk. Genetic studies suggest heritability of ~40% for TB susceptibility, though environmental factors predominate.

Asymptomatic Presentation

• No symptoms: LTBI individuals have no cough, fever, night sweats, weight loss, hemoptysis, or constitutional symptoms. These findings are absent by definition; their presence indicates active TB disease, not LTBI.
• Normal physical examination: General appearance is entirely well; there are no abnormal lung auscultatory findings, no lymphadenopathy, no hepatosplenomegaly, no signs of systemic disease.

Radiographic Findings

• Normal or no radiographic abnormality: Chest X-ray is typically normal in LTBI. However, some individuals with LTBI have incidental radiographic findings from their prior TB infection: apical-posterior infiltrates (common site of reactivation TB), fibrotic scarring, hilar lymphadenopathy, pleural thickening, or rarely calcified nodules. These radiographic findings DO NOT diagnose LTBI; they are incidental findings in individuals with positive immune testing and no clinical evidence of active disease. A calcified granuloma (tuberculoma) may persist as evidence of prior infection.

Clinical Variants and Special Circumstances

• Recent TB contact without yet developed immunity: Individuals with documented TB exposure who have not yet seroconverted (negative tuberculin skin test, negative IGRA at baseline) but have recent exposure risk require serial testing 8–12 weeks post-exposure to detect LTBI. These contacts are at highest risk of rapid progression if they become infected.

• LTBI in immunocompromised individuals: While LTBI itself has no clinical manifestations, immunocompromised persons with LTBI (HIV with CD4 >200, on TNF inhibitors, etc.) require urgent consideration for preventive therapy given their high progression risk. These individuals may present for evaluation of TB risk before any symptoms develop.

• Incidental LTBI discovery during screening: Many LTBI cases are identified opportunistically during routine screening (occupational health, immigration screening, contact investigation, pre-organ transplant evaluation), in which case the patient is entirely asymptomatic and unaware of TB exposure history.

• High-risk clinical scenarios: Patients presenting with conditions associated with LTBI progression (new diagnosis of HIV, initiation of TNF inhibitors, new diagnosis of diabetes) should be assessed for LTBI; these individuals are asymptomatic for TB but present for management of their underlying condition.

Physical Examination Findings: Key Negatives

• No respiratory findings: Normal breathing, no crackles, wheezes, or diminished breath sounds (which would suggest pulmonary infiltrate and active disease).
• No constitutional findings: Normal weight and nutrition, no cachexia, no fever.
• No lymphadenopathy: Peripheral lymph nodes are normal; no hilar or mediastinal lymphadenopathy on examination (would require imaging to exclude).

Step 1 — exclude active disease before any drug is given

• Symptom screen plus chest radiograph in every person with a positive TST or IGRA; obtain sputum for AFB smear, culture, and nucleic acid amplification if symptoms or an abnormal film are present. Treating undiagnosed active TB with a one- or two-drug latent regimen selects for acquired resistance — this sequencing error is the most commonly tested management mistake.

First-line therapy (CDC/National Tuberculosis Controllers Association 2020 LTBI guidelines preferentially recommend short-course rifamycin-based regimens)

• **Rifamycin + isonicotinic hydrazide combination — weekly isoniazid plus rifapentine for 12 doses (3HP)**: directly observed or self-administered; shortest regimen, highest completion rates. Rifapentine is dosed by weight; isoniazid inhibits mycolic acid synthesis and rifamycins inhibit DNA-dependent RNA polymerase.
• **Rifamycin monotherapy — rifampin 600 mg daily for 4 months (4R)**: preferred when isoniazid is not tolerated or in isoniazid-resistant contacts; lower hepatotoxicity than isoniazid.
• **Isoniazid + rifampin daily for 3 months (3HR)**: an acceptable short-course alternative.
• Isoniazid 300 mg daily for 6 or 9 months: now an alternative, reserved for rifamycin intolerance, rifamycin drug–drug interactions, or rifampin-resistant contacts. Add pyridoxine (vitamin B6) 25–50 mg daily for pregnancy, HIV, diabetes, alcohol use disorder, renal failure, or malnutrition.

Special situations and escalation

• HIV: rifamycins induce CYP3A4; check antiretroviral compatibility (rifabutin is the usual substitute with boosted protease inhibitors). CDC/DHHS support 3HP with several integrase- and NNRTI-based regimens.
• Pregnancy: isoniazid with pyridoxine is the standard; 3HP is not recommended. Treatment is often deferred until after delivery unless HIV-positive or a recent contact.
• MDR-TB contacts: no standard regimen — refer to a TB expert; fluoroquinolone-based (levofloxacin) prophylaxis is used.
• Window prophylaxis: children <5 years and severely immunocompromised close contacts are treated empirically despite an initially negative test, then retested at 8–12 weeks.

Contraindicated / avoid

• Rifampin–pyrazinamide for 2 months: withdrawn by CDC after fatal hepatotoxicity.
• Monotherapy when active TB has not been excluded; and withholding therapy on the basis of age alone — that older teaching has been abandoned.

Complications of untreated latent infection

• Reactivation pulmonary TB: loss of TNF-α– and IFN-γ–dependent granuloma integrity permits resumption of aerobic replication in the high-oxygen apical-posterior segments; signalled by cough >2–3 weeks, hemoptysis, night sweats, weight loss, and upper-lobe cavitation. The patient becomes infectious — airborne isolation is required immediately.
• **Disseminated (miliary) TB and TB meningitis**: hematogenous spread in profound immunosuppression (HIV with low CD4, infants, TNF-α inhibitor use). Miliary millet-seed nodules on imaging, or basilar meningitis with cranial nerve palsies, hypoglycorrhachia and lymphocytic pleocytosis. Both are emergencies — empiric four-drug therapy (plus corticosteroids for meningitis and pericarditis) should not await culture.
• Acquired drug resistance: giving a latent regimen to a patient with unrecognized active disease amounts to functional monotherapy.
• Paradoxical worsening / IRIS: unmasking of subclinical TB after antiretroviral initiation or after stopping a TNF-α inhibitor; fever and enlarging nodes despite therapy.

Complications of therapy

• Isoniazid hepatotoxicity: CYP2E1-generated hydrazine metabolites; risk rises with age, alcohol, chronic liver disease, and the postpartum period. Anorexia, nausea, RUQ pain, dark urine, jaundice with transaminase elevation. Fulminant hepatic failure is an emergency — stop the drug for symptomatic transaminase elevation ~3× ULN or asymptomatic elevation ~5× ULN (ATS/CDC monitoring guidance).
• Isoniazid peripheral neuropathy: isoniazid forms hydrazones with pyridoxal-5-phosphate and increases its urinary loss; stocking-glove paresthesias — prevented by pyridoxine. Massive overdose causes refractory seizures and anion-gap acidosis, treated with high-dose IV pyridoxine.
• Isoniazid drug-induced lupus (positive ANA, arthralgias), especially in slow acetylators.
• Rifamycin effects: potent CYP450 induction causing oral contraceptive failure, subtherapeutic warfarin, and transplant rejection; harmless orange discoloration of urine, tears, and contact lenses; and, with intermittent rifapentine or rifampin, a flu-like syndrome with fever, thrombocytopenia, hemolysis, acute interstitial nephritis, or hypotension — these hypersensitivity reactions mandate stopping the rifamycin.

• Positive TST or IGRA → symptom screen and chest radiograph is always the single best next step. No latent regimen is started until active disease is excluded; monotherapy in active TB breeds resistance.
• IGRA is preferred in BCG-vaccinated patients and in those unlikely to return for TST reading. IGRAs use ESAT-6 and CFP-10, antigens absent from BCG and from most nontuberculous mycobacteria (exceptions: M. kansasii, M. marinum, M. szulgai), so a positive IGRA in a foreign-born vaccinated patient is real infection, not vaccine cross-reactivity.
• TST cut-offs are the classic tested detail: ≥5 mm for HIV, recent close contacts, fibrotic changes on chest film, transplant recipients, and other immunosuppression (including chronic prednisone ≥15 mg/day); ≥10 mm for recent immigrants from high-burden countries, injection drug users, healthcare and correctional workers, children <5, and comorbidities such as diabetes, silicosis, ESRD, and gastrectomy; ≥15 mm for everyone else.
• 3HP (weekly isoniazid–rifapentine × 12) and 4R (rifampin × 4 months) are the CDC/NTCA-preferred regimens. "Nine months of isoniazid" is the classic outdated distractor — it is now an alternative, not first line.
• Pyridoxine with isoniazid in pregnancy, HIV, alcohol use disorder, diabetes, renal failure, and malnutrition prevents peripheral neuropathy; it does not prevent hepatotoxicity.
• Orange body fluids on rifampin require reassurance, not discontinuation — but warn about oral contraceptive failure and check interacting drugs.
• TNF-α inhibitors are the association examiners love: screen for LTBI before starting infliximab/etanercept/adalimumab, because TNF-α maintains the granuloma.
• Once positive, always positive — do not repeat TST/IGRA after treatment; follow subsequent exposures clinically with symptom review and imaging. And a negative test does not exclude infection in advanced HIV (anergy) or within the 8–12-week window after exposure.